feasibility of combined neuroprotection in patients with AIS convincingly are substantiated by leading Ukrainian neurologists. The aim is to evaluate the economic feasibility of combined regimens of neuroprotection compared with the traditional. METHODS: Analysis of the results of comparative clinical trial of three neuroprotective regimens therapy of patients with moderate and severe AIS: traditional ϩ citicoline (1 regimen); traditional ϩ citicoline ϩ actovegin (2 regimen); 3 regimen: traditional (pentoxifylline, heparin, acetylsalicylic acid, mannitol) (S. M. Vinychuk, O. A. Pustova, V.O. Mokchnach et al., 2008) was carried out. Cost-effectiveness analysis was used. Using a decision tree comparing the economic burden of the three regimens for one year was carried out. RESULTS: The number of patients who recovered completely after three months were used as efficacy. The efficacy for 1, 2 and 3 regimens were respectively 29.6%, 38.9% and 23.3%. Direct costs of the treatment regimens were $ 1.015; $ 1.186; $ 617 for 1, 2 and 3 regimens, respectively. Incremental cost-effectiveness ratio (ICER) for 1 and 2 regimens were respectively $6.317, $3.647. The economic burden per one patient for one year were $ 7006; $ 6511; and $ 6930 for 1, 2 and 3 regimens, respectively. CONCLUSIONS: The use of regimen 1 and regimen 2 provides greater efficacy and needs greater cost.
OBJECTIVES:
To estimate the health care resource utilization and direct costs of cardioembolic stroke in patients treated in public hospitals of the Region of Madrid (Spain). METHODS: An observational, prospective study was performed in 5 Neurology services from hospitals in the Region of Madrid, 2 with stroke units (SU) and 3 without stroke units (wSU) . Patients with a diagnosis of cardioembolic stroke with Յ48-hours were recruited in a 4-month period in 2012. Patients' socio-demographic, clinical data: disability (modified Rankin scale, mRs), hospital stay and mortality; complications and health care resource utilization (hospitalisation, inpatient and at discharge rehabilitation, medication, laboratory tests and specific therapeutic interventions) were collected. Unitary costs were obtained from national health care database and the Spanish Catalogue of Medicinal Products (€, year 2012) . RESULTS: Preliminary results from 76 patients (25 SU, 51 wSU) were: mean age, 74.2Ϯ1.42; 64.5% female; mean mRs at discharge, 2.02Ϯ0.20; non-valvular atrial fibrilation was the main cause of cardioembolic stroke (28.9%); mean length of stay, 10.1Ϯ1.14 days; mortality, 5.3%; 42 patients (68.4%) needed in-patient rehabilitation and 48 patients (63.2%) needed rehabilitation after hospital discharge; 22 patients (28.9%) suffered hospital complications (63.6% of them suffered infections, 27.3% cardiovascular complications and 59.1% others). Health care resource utilization differences between SU and wSU hospitals were found in: length of stay (7.2Ϯ1.26 days, SU; 11.6Ϯ1.55 days, wSU; p-valueϭ0.014) and specific therapeutic interventions (41.7%, SU; 8.0%, wSU; p-valueϭ0.001). The overall 4-month cost per patient was 13,647€ (49.2%, hospital stay; 24.8%, rehabilitation at discharge). CONCLUSIONS: Cardioembolic stroke imposes significant economic burden for the Public Health System in the Region of Madrid. Key cost drivers were hospital stay and patients' rehabilitation at discharge. Patient management in SU hospitals was associated with more specific therapeutic interventions and shorter hospital stay than hospitals wSU.
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ASSESSMENT OF THE HOSPITAL COSTS OF MITRAL REGURGITATION (MR) PATIENTS, A FRENCH NATIONAL HOSPITAL DATABASE ANALYSIS
Cros S 1 , Levesque K 2 , Bufi L 3 , Caranhac G 4 , Gotlieb L 3 1 Abbott Vascular International BVBA, Diegem, Belgium, 2 Abbott Vascular, Rungis Cedex, NT, Canada, 3 Abbott Vascular, DIEGEM, Belgium, 4 HOX-COM Analytiques, Vincennes, France OBJECTIVES: To evaluate the annual acute and long-term hospitalizations cost of MR from a French National Payer perspective. METHODS: A 12 months retrospective population-based study was conducted using the 2009 -2010 French Medical Information System (PMSI). This exhaustive database covers all public and private hospitals in France and it is based on standardized hospital discharge reports. Each patient is identified using a unique anonymous identification number allowing a longitudinal follow-up. Extracted variables included patients' demographics, outcomes, acute hospital and post-discharge resource utilizations. RESULTS: 19,868 MR patients were identified and analyzed in two sub-groups depending on their therapeutic management. In the surgical group (nϭ4,099), the index hospitalization length of stay was 17 days, 77% of patients were discharged to a rehabilitation facility and the average re-hospitalization rate was of 33% over a 6 month period. The average total cost per patient was €22.152. In the non-surgical group (nϭ15,769), patients were hospitalized on average 3.1 times over 12 months with an average length of stay of 7.7 days. Among those patients, 24% were admitted to a rehabilitation facility (on average 1.5 times) with an average length of stay of 27.9 days. The average total cost per patient was €12.177, varying between €9.957 to €13.538, without and with heart failure respectively. Detailed analysis showed 2 to 3 times higher costs in the 9th and 10th percentiles. By sub-group, the average cost of the 10th percentile was €50.268 for the surgical group and €36.503 for the nonsurgical group. CONCLUSIONS: The total observed cost in this population was €283 million over 12 months. Significant differences were observed in cost and resource used between the surgical and non-surgical groups and depending on type of surgery or presence of heart failure within each subgroup. This is the first study reporting hospital costs associated to MR in France. OBJECTIVES: Cardiovascular diseases (CVDs) imposes a burden to society in terms' of mortality, morbidity and economic losses. The aim of this study was to estimate the cost of CVDs in Serbia in 2009 from the perspective of the society. METHODS: For the purpose of the study CVD was defined by the International Classification of Disease 10 revision, as the following diagnosis: hypertension, coronary heart disease, cardiomyopathy, heart failure and cerebrovascular disease. The prevalence, top-down method was used to quantify the annual cardiovascular costs. Productivity losses were estimated using the human capital approach and the friction cost method. Data were collected from Serbian Health Insurance Fund and National Public Health Institute "Batut". A discount rate of 5% was used to convert all future lifetime earnings into the present value. RESULTS: The total direct costs of CVD in 2009 were € 400 million. The majority of total costs (€ 514.3 million) were for: medication (29.94%), hospital days (28.97%) and hospital inpatient care -surgical and diagnostic interventions (17.84%). Indirect costs (mortality and morbidity) accounted for 22.15% of total costs. The results showed that more than half a million working days were lost due to incapacity resulting from CVDs. The results were robust to a change in Ϯ20% of volume or the unit price of all direct and indirect cost and to discount rate 2% and 10%. CONCLUSIONS: The total CVD in 2009 represented approximately 1.8% of the Serbian gross domestic product. The results of study would be valuable to health policy makers to bridge the gap between invested resources and needs, in order to improve cardiovascular disease outcomes.
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COST OF CARDIOVASCULAR DISEASES IN SERBIA
PCV32 THE COST OF DIABETES COMPLICATIONS IN BELGIUM
Lamotte M, Chevalier P IMS Health, Vilvoorde, Belgium OBJECTIVES: The risk of cardiovascular risk is higher in patients with diabetes but what with the cost of this complication? The aim of this study was to compare the cost of cardiovascular events in patients with and without diabetes in Belgium. METHODS: Cost of cardiovascular events among hospitalized patients were estimated using the longitudinal IMS Hospital Disease Database (2008), including data on 34.3% of Belgian hospital beds, combined with Belgian population data. Stays were identified based on ICD-9 or DRG coding. Cardiac disease included myocardial infarction (MI; ICD-9:410), angina (ICD-9: 413) and heart failure (ICD-9: 428). Cerebrovascular disease (CVD) was defined as stroke (APR-DRG:045;046) and Transient Ischemic Attack (TIA; DRG:047). Diabetes was defined with the ICD-9 codes 249 and 250. Cost comparisons were made using a Wilcoxon non-parametrical test.
A367
V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 -A 5 7 5 RESULTS: An MI in a diabetic patient was 35% more expensive compared to a non diabetic (€7,483 vs. €5,549; pϽ0.001). In angina and heart failure the difference was less pronounced, nevertheless the cost was respectively 22% and 13% higher (angina: €2,570 vs. €2,101; pϭ0.01, heart failure: €8,776 vs. €7,757; pϽ0.001). Stroke was 8% more expensive and TIA 17% more expensive (stroke: €9,508 vs. €8,804; TIA: €4,802 vs. €4,109; both pϽ0.001). Reason for this higher cost is the longer length of stay varying from 1 day in angina to 3 days in MI. The percentage of women was higher in the diabetic group (50% vs. 47%; pϽ0.05) and diabetic patients were on average 1.8 years older (72.8 vs. 71.0; pϽ0.01). A regression analysis learned that age was the most important cost driver for all outcomes and diabetes was an independent driver for MI and stroke. CONCLUSIONS: Patients with diabetes do not only have a higher risk of cardiovascular events, in case they have an event this event is significantly more expensive.
PCV33 ECONOMIC BURDEN OF CARDIOVASCULAR DISEASES IN RUSSIAN FEDERATION Kontsevaya A, Kalinina A National Research Center for Preventive Medicine, Moscow, Russia
OBJECTIVES: To study the economic burden of cardiovascular diseases (CVD) in Russian Federation in [2006] [2007] [2008] [2009] . METHODS: The economic burden was calculated by the cost of illness method. The calculations included direct costs of health care system and indirect costs, associated with premature death in working age and disability. We used official statistics of health care resources utilization, associated with CVD (hospital days, outpatients visits, emergency visits), the results of pharmacoepidemiological surveys of CVD, mortality and disability statistics in Russia in [2006] [2007] [2008] [2009] . RESULTS: The total economic burden of CVD increased from 20.6 billions of euro in 2006 till 26.6 billion of euro in 2009 what was equal to 3.1-2.8% of GDP of Russian Federation. The increasing of the burden was mainly caused by the price increasing and in some degree by the increasing of PCI in CHD patients in recent years. Direct costs accounted 21.3% of total cost of CVD (5.7 billions of euro), indirect costs -78.7% (20.9 billions of euro) in 2009. Indirect costs mainly consisted of the GDP losses because of premature death of working age men. CHD represented 37.8%, cerebrovascular diseases 17.1 % and hypertension -10.8% of overall CVD costs. In-hospital care represented 47.5% of direct costs, outhospital visits -21.8%, medication -20.7%, PCI -4.1% and emergency care 4.1% of direct costs in 2009, respectively. CHD represented 45.3% of direct cost, because of large duration of hospitalization and PCI costs. CONCLUSIONS: CVD is a big public health challenge in Russia. The results of economic burden assessment should help policy makers evaluate policy impact and prioritize expenditures.
PCV34 THE ECONOMIC COST OF ACUTE CORONARY SYNDROME IN TURKEY
Cakir B 1 , Caliskan Z 1 , Ergun H 2 , Erol C 2 , Gumusel B 1 , Tokgozoglu L 1 , Dayioglu M 3 1 Hacettepe University, Ankara, Turkey, 2 Ankara University, Ankara, Turkey, 3 Eli Lilly and Company, Istanbul, Turkey OBJECTIVES: Acute coronary syndrome (ACS) is a major complication of the atherosclerotic process that may lead to myocardial necrosis. It is a medical emergency and requires immediate hospital admission. The aim of the present study was to assess the epidemiology and economic burden of ACS in Turkey, where the population is aging, incidence of cardiovascular diseases tend to increase, yet, knowledge on ACS-related health expenditures are inconclusive. METHODS: For this purpose, the 2008 data acquired from 28 hospitals of the Diagnose-Related Group Project were evaluated, accounting for 6.5% of the population. Accordingly, the number of hospitalized patients with an ACS diagnosis in 2008 was 102,677. The majority of patients with ACS were Ն40 years of age, and thus, all statistical analyses were limited to this age group. RESULTS: The rate of new ACS admissions was calculated as 444 per 100,000. With the assumption (based on earlier published work) that 1/3 of ACS patients failed to reach health care settings, the prevalence of new ACS cases in the general population was estimated to be 666 per 100,000. The average in-patient fatality rate was 29% (41% for females and 24% for males) among the Ն40 years of age group. The economic burden of ACS in Turkey was 1,778,372,874 USD. The direct cost was 151,261,411 USD, whereas the indirect cost was 1,364,742,497 USD. The cost due to the loss of public tax was 262,368,964 USD. Medication costs, which are annually 590 USD per patient on average, encountered a small percentage of total expenditures, compared with that of hospital services and the loss of public tax. CONCLUSIONS: To prevent ACS, health policies targeting risk factors should be emphasized in an effort to improve efficacy and efficiency of cost.
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COSTS OF TREATING CARDIOVASCULAR DISEASES IN GERMANY: A SYSTEMATIC LITERATURE REVIEW
Xu W 1 , Hensen M 1 , Steinle T 2 , Pelosi C 3 1 Pharmerit International, Rotterdam, The Netherlands, 2 Amgen (Europe) GmbH, München, Germany, 3 Amgen, Zug, Switzerland OBJECTIVES: Germany reformed its hospital reimbursement scheme to servicebased payment to diagnosis-related groups. Hospitals in Germany might be more cost-conscious in treating patients compared to the pre-reform period. This study identified the post-reform individual-level direct medical costs and costs over time of several cardiovascular diseases (CVDs), including myocardial infarction (MI), heart failure (HF), peripheral artery diseases (PADs), and stroke, from the perspective of Statutory Health Insurance in Germany. METHODS: A systematic review (January 2003 to May 2012) was conducted in Pubmed, Embase, CRD, TIBORDER, and German dissertation database to identify relevant English or German language publications. RESULTS: The search identified 157 publications, of which 10 met the predefined inclusion/exclusion criteria for review: 5 about MI, 2 about HF, 1 about PAD, and 5 about stroke. The direct medical costs of MI were between € 11,672 -12,372/patient in the 1st year after the event; 50-60% of the costs incurred in the acute phase. During the 13-18 months after the event, the costs were estimated to be € 981/patient. Direct medical costs of severe chronic HF were € 27,700/patient annually. Direct medical costs of hospitalized PAD were € 7,674/patient in the 1st year, including € 4,186 in the acute phase. In months 13-18, the costs were € 1,172/ patient. For stroke of all types, direct medical costs in the 1st year were € 11,408/ patient, half of which were incurred in the first 4 weeks after the event. For ischemic stroke, direct medical costs in the 1st year were € 17,864 -€ 18,517/patient, with 29% incurred in the acute phase. In the subsequent 4 years, annual direct medical costs were € 5,479/patient. CONCLUSIONS: In Germany, treating CVDs triggers substantial direct medical costs, especially in the acute phases. Hospitalization and rehabilitation are two major cost drivers.
